Design and development of halogenated chalcone derivatives as potential anticancer agents

Tropical Journal of Pharmaceutical Research

Volumn 13, Issue 1, 2014, Pages 73-80

  Jain, Upendra K ^a   Bhatia, Richa K ^a   Rao, Akkinepally R ^b   Singh, Ranjit ^c   Saxena, Ajit K ^d   Sehar, Irum ^d  

^a Chandigarh College of Pharmacy   (India)

^b KAKATIYA UNIVERSITY   (India)

^c SHOBHIT UNIVERSITY   (India)

^d CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer activity; Dock scores; Halogenated chalcones; Interleukin 1beta converting enzyme

Indexed keywords

(3S ) N METHANESULFONYL 3 [[1 [N (2 NAPHTOYL) L VALYL] L PROLYL]AMINO] 4 OXOBUTANAMIDE; 1 (4 BROMO PHENYL) 3 (2 TRIFLUOROMETHOXYPHENYL) PROPENONE; 1 (4 BROMO PHENYL) 3 (2,4 DIMETHOXY PHENYL) PROPENONE; 1 (4 BROMO PHENYL) 3 (2,6 DICHLORO 3,4 DIMETHOXY PHENYL) PROPENONE; 3 (2 BROMO 5 METHOXY PHENYL) 1 (4 BROMOPHENYL) PROPENONE; 3 (2 BROMO 5 METHOXY PHENYL) 1 (4 METHOXYPHENYL) PROPENONE; 3 (2 FLUORO 4 METHOXY PHENYL) 1 (4 PHENOXYPHENYL) PROPENONE; 3 (2 FLUORO 6 METHOXY PHENYL) 1 (4 PHENOXYPHENYL) PROPENONE; 3 (2,6 DICHLORO 3,4 DIMETHOXY PHENYL) 1 (4 METHOXY PHENYL) PROPENONE; CHALCONE DERIVATIVE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LIVER CANCER; NEUROBLASTOMA; OVARY CANCER; PROSTATE CANCER;

EID: 84893394390     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v13i1.11     Document Type: Article

References (21)

1. Park EJ, Park HR, Lee JS, Kim. Licochalcone A: an inducer of cell differentiation and cytotoxic agent from Pogostemon cablin. Planta Med 1998; 64 (5): 464-466.
2. Ko HH, Tsao LT, Yu KL, Liu CT, Wang JP, Lin CN. Structure-activity relationship studies on chalcone derivatives. The potent inhibition of chemical mediators release. Bioorg Med Chem 2003; 11(1): 105-111.
3. Nielsen SF, Christensen SB, Cruciani G, Kharazmi A, Liljefors T. Antileishmanial chalcones: Statistical design, synthesis and three-dimentional quantitative structure-activity relationship analysis. J Med Chem 1998; 41(24): 4819-4832.
4. Cabrera M, Simoens M, Falchi G, Lavaggi ML, Piro OE, Castellano EE, Vidal A, Azqueta A, Monge A, de Ceráin AL, Sagrera G, Seoane G, Cerecetto H, González M. Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. Bioorg Med Chem 2007; 15: 3356-3367.
5. Ducki S, Rennison D, Woo M, Kendall A, Chabert JF, McGown AT, Lawrence NJ. Combretastatin-like chalcones as inhibitors of microtubule polymerization: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2003; 17: 7698-7710.
6. Yang Y, Xia P, Bastow KF, Nakanishi Y, Lee KH. Antitumor agents. Part 202: novel 2'-amino chalcones: design, synthesis and biological evaluation. Bioorg Med Chem Lett 2000; 10: 699-701.
7. Boumendjel A. 4-Hydroxy-6-methoxyaurones with highaffinity binding to cytosolic domain of Pglycoprotein. Chem Pharm Bull 2002; 50: 854-856.
8. Bois F, Beney C, Boumendjel A, Mariotte AM, Conseil G, Pietro AD. Halogenated chalcones with high-affinity binding to p-glycoprotein: potential modulators of multidrug resistance. J Med Chem 1998; 41: 4161-4164.
9. Ivanova AB. Comparative study on the mdr reversal effects of selected chalcones. Int J Med Chem 2011; Article ID 530780: 1-7.
10. Discovery Studio, Version 21 (2007), Accelrys Inc: San Diego, CA, USA.
11. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J Natl Cancer Inst 1991; 83: 757-766.
12. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric Cytotoxic Assay for Anticancer-Drug Screening. J Natl Cancer Inst 1990; 82: 1107-1112.
13. Okamoto Y, Anan H, Nakai E, Morihira K, Yonetoku Y, Kurihara H, Sakashita H, Terai Y, Takeuchi M, Shibanuma T, Isomura Y. Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex. Chem Pharm Bull 1999; 47: 11-21.
14. Brooks BR, Bruccoleri RE, Olafson D, Swaminathan S, Karplus M. CHARMm. A program for macromolecular energy, minimization and dynamics calculations. J Comput Chem 1983; 4:187-217.
15. Chem Draw Ultra-version, CambridgeSoft Inc, Cambridge, USA, 2007; 50.
16. McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK. Gaussian docking functions. Biopolymers 2003; 68: 76-90.
17. Stalh M, Rarey M. Detailed analysis of scoring functions for virtual screening. J Med Chem 2001; 44: 1035-1042.
18. Gehlhaar DK, Verkhivker GM, Rejto PA, Sherman CJ, Fogel DB, Fogel LJ, Freer ST. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Chem Biol 1995; 2: 317-324.
19. Vigers GP, Rizzi JP. Multiple Active Site Corrections for Docking and Virtual Screening. J Med Chem 2004; 47: 80-89.
20. Matteson DS. (Alkoxyalkyl) boronic ester intermediates for asymmetric synthesis. Organometallics 1996, 15: 152-163.
21. Keith PW, Jo-Anne FB, John AT. Structure and mechanism of interleukin-lβ converting enzyme. Nature 1994, 370: 270-275.